(S)-(-)-1-Phenylethanamine
Based on 1 Customer Validation
(S)-(-)-1-Phenylethanamine (S-(-)-α-Phenylethylamine; L-(-)-α-Methylbenzylamine) is a S-isomer of 1-Phenylethanamine (HY-W012848). (S)-(-)-1-Phenylethanamine can be used as a pharmaceutical intermediate for the synthesis of various active compounds.
Para uso exclusivo en investigación. No vendemos a pacientes.
- Pureza: 99.84%
- No. CAS: 2627-86-3
- Fòrmula: C8H11N
- Peso molecular:121.18
-
Almacenamiento:
4°C, protect from light
* In solvent : -80°C, 6 months; -20°C, 1 month (protect from light)
To place orders, for customer services and technical support, please contact: MedChemExpress USA
Tel: 609-228-6898 E-mail: [email protected] [email protected]
-
Actividad biológica
-
Chemical Information
-
Solvente y solubilidad
- Pureza y Documentación
- Referencias
-
Help & FAQs
Actividad biológica
1-Phenylethanamine is a potential central nervous system stimulant and can be used to synthesize the tyrosine kinase inhibitor CLM3 (HY-164413)[1].
(S)-(-)-1-Phenylethanamine (Compound 7z) can be used as a drug intermediate for synthesizing microtubule polymerization inhibitors[2].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
Chemical Information
-
No. CAS 2627-86-3
-
Appearance Liquid (Density: 0.952 g/cm3)
-
Peso molecular 121.18
-
Fòrmula C8H11N
-
Color Colorless to light yellow
-
SMILES
N[C@@H](C)C1=CC=CC=C1
-
Synonyms
S-(-)-α-Phenylethylamine; L-(-)-α-Methylbenzylamine
-
Envío
Room temperature in continental US; may vary elsewhere.
-
Almacenamiento
4°C, protect from light
* In solvent : -80°C, 6 months; -20°C, 1 month (protect from light)
Solvente y solubilidad
DMSO : ≥ 50 mg/mL (412.61 mM; Hygroscopic DMSO has a significant impact on the solubility of product, please use newly opened DMSO)
* "≥" means soluble, but saturation unknown.
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month (protect from light). When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month (protect from light). When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
Select the appropriate dissolution method based on your experimental animal and administration route.
- For the following dissolution methods, please ensure to first prepare a clear stock solution using an In Vitro approach and then sequentially add co-solvents:
- To ensure reliable experimental results, the clarified stock solution can be appropriately stored based on storage conditions. As for the working solution for In Vivo experiments, it is recommended to prepare freshly and use it on the same day.
- The percentages shown for the solvents indicate their volumetric ratio in the final prepared solution. If precipitation or phase separation occurs during preparation, heat and/or sonication can be used to aid dissolution.
Add each solvent one by one: 10% DMSO 40% PEG300 5% Tween-80 45% Saline
Solubility: ≥ 0.83 mg/mL (6.85 mM); Clear solution
This protocol yields a clear solution of ≥ 0.83 mg/mL (saturation unknown).
Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (8.3 mg/mL) to 400 μL PEG300, and mix evenly; then add 50 μL Tween-80 and mix evenly; then add 450 μL Saline to adjust the volume to 1 mL.
Preparation of Saline: Dissolve 0.9 g sodium chloride in ddH₂O and dilute to 100 mL to obtain a clear Saline solution.
Add each solvent one by one: 10% DMSO 90% (20% SBE-β-CD in Saline)
Solubility: ≥ 0.83 mg/mL (6.85 mM); Clear solution
This protocol yields a clear solution of ≥ 0.83 mg/mL (saturation unknown).
Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (8.3 mg/mL) to 900 μL 20% SBE-β-CD in Saline, and mix evenly.
Preparation of 20% SBE-β-CD in Saline (4°C, storage for one week): 2 g SBE-β-CD powder is dissolved in 10 mL Saline, completely dissolve until clear.
Please enter the basic information of animal experiments:
-
-
-
-
Recommended: Prepare an additional quantity of animals to account for potential losses during experiments.
Please enter your animal formula composition:
-
%DMSO +
Recommended: Keep the proportion of DMSO in working solution below 2% if your animal is weak.
-
%+
-
+%Tween-80 + +
-
%Saline +
The co-solvents required include: DMSO, . All of co-solvents are available by MedChemExpress (MCE). , Tween 80. All of co-solvents are available by MedChemExpress (MCE).
Working solution concentration: 0.22 mg/mL
Method for preparing stock solution: mg drug dissolved in μL DMSO. Stock solution concentration: mg/mL. * In solvent : -80°C, 6 months; -20°C, 1 month (protect from light)
1. Take μL DMSO stock solution;
2. Add μL .
μL , mix evenly;
3. Then add μL Tween 80, mix evenly;
4. Then add μL
Please ensure that the stock solution in the first step is dissolved to a clear state, and add co-solvents in sequence. You can use ultrasonic heating (ultrasonic cleaner, recommended frequency 20-40 kHz), vortexing, etc. to assist dissolution.
Pureza y Documentación
-
Ficha de datos (273 KB)
-
SDS (642 KB)
- English - EN (642 KB)
- Français - FR (642 KB)
- Deutsch - DE (642 KB)
- Norwegian - NO (642 KB)
- Español - ES (642 KB)
- Swedish - SV (642 KB)
- Italian - IT (642 KB)
- Korean - KR (642 KB)
- Portuguese - PT (642 KB)
-
Instrucciones de manejo (2659 KB)
Referencias
[1]. Kaiser DG, et al. Isomeric inversion of ibuprofen (R)-enantiomer in humans. J Pharm Sci. 1976 Feb;65(2):269-73. [Content Brief]
[2]. Reddy CN, et al. 7S,15R-Stereoisomer of phenylethylamino derivative of colchicine exhibits potent in-vitro and in-vivo anti-cancer activity against prostate Cancer: Assessing the impact of stereochemistry on biological activity. Bioorg Chem. 2025 Apr;157:108262. [Content Brief]
Complete Stock Solution Preparation Table
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month (protect from light). When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.
| Optional Solvent | Concentration Solvent Mass | 1 mg | 5 mg | 10 mg | 25 mg |
|---|---|---|---|---|---|
| DMSO | 1 mM | 8.2522 mL | 41.2609 mL | 82.5219 mL | 206.3047 mL |
| 5 mM | 1.6504 mL | 8.2522 mL | 16.5044 mL | 41.2609 mL | |
| 10 mM | 0.8252 mL | 4.1261 mL | 8.2522 mL | 20.6305 mL | |
| 15 mM | 0.5501 mL | 2.7507 mL | 5.5015 mL | 13.7536 mL | |
| 20 mM | 0.4126 mL | 2.0630 mL | 4.1261 mL | 10.3152 mL | |
| 25 mM | 0.3301 mL | 1.6504 mL | 3.3009 mL | 8.2522 mL | |
| 30 mM | 0.2751 mL | 1.3754 mL | 2.7507 mL | 6.8768 mL | |
| 40 mM | 0.2063 mL | 1.0315 mL | 2.0630 mL | 5.1576 mL | |
| 50 mM | 0.1650 mL | 0.8252 mL | 1.6504 mL | 4.1261 mL | |
| 60 mM | 0.1375 mL | 0.6877 mL | 1.3754 mL | 3.4384 mL | |
| 80 mM | 0.1032 mL | 0.5158 mL | 1.0315 mL | 2.5788 mL | |
| 100 mM | 0.0825 mL | 0.4126 mL | 0.8252 mL | 2.0630 mL |
(S)-(-)-1-Phenylethanamine Related Classifications
HY-75095 Related Classifications
Powered by Bioz